Author

Jia-Tao Zhang

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

PRODH promotes osimertinib drug-tolerant persistence in EGFR-mutant NSCLC by activating mitochondrial transcription.

The emergence of drug-tolerant persister (DTP) cells poses a major obstacle to durable responses to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC). However, how metabolic programming orchestrates this transient and reversible adaptive resistance remains largely unexplored. Here...

Xiang Meng, Liang Chen, Yu-Qing Yang et al. · Cancer Letters · 0 citations

Review Open access Jul 2026

Targeting Classical EGFR Mutations in Lung Cancer: Twenty Years of Progress and Beyond

Simple Summary Classical EGFR mutations have transformed the management of non-small cell lung cancer across metastatic, resectable, and unresectable locally advanced settings. This review traces the evolution from early-generation EGFR tyrosine kinase inhibitors to osimertinib and contemporary combination regimens, an...

Y. Uehara, H. Hatano, Jia-Tao Zhang et al. · Cancers · 0 citations